Clinical TrialsEnrollment for the Phase 3 Netherton Syndrome study is ongoing, with QRX003 potentially becoming the first FDA-approved therapy for this condition.
Financial StabilityThe cash reserves are expected to sustain operations beyond the Phase 3 readout of the Netherton Syndrome study, providing financial stability.
Research And DevelopmentA new research agreement with University College Cork aims to develop a topical Rapamycin formulation for rare diseases, without any upfront or milestone payments.